Bob Ryder went to medical school and undertook junior medical and research jobs in South Wales before moving to become Senior Registrar in Sheffield. He has worked as a Consultant Physician with an interest in Diabetes and Endocrinology at City Hospital (formally Dudley Road Hospital), Birmingham since 1991. Over the years special interests have included photographic screening for diabetic retinopathy – he undertook much of the groundwork behind the current national eye screening programme; diabetic hypoglycaemia unawareness; diabetic autonomic neuropathy; diabetic impotence; clinical use of IT; treating to target; relative risks and benefits of pioglitazone (especially its insufficiently recognised cardioprotective properties which might well complement those of empagliflozin and liraglutide). He runs the Association of British Clinic Diabetologists (ABCD) website and leads the ABCD nationwide audits of new therapies, most recently establishing for this purpose an ABCD presence on N3, the national broadband network of the NHS. Current audits include dapagliflozin, canagliflozin, empagliflozin, liraglutide, exenatide qw, and degludec. He is chief investigator for the NIHR supported, multicentre, ABCD Endobarrier study, “REVISE-Diabesity” (https://youtu.be/xRcnMBOdb58), and the recently commenced “End-OSA” study of Endobarrier in diabetes with Obstructive Sleep Apnoea (https://youtu.be/y1zm0Scq6YM). A current major interest is community diabetes and a project which won the QIC best primary and/or community initiative in 2014 (https://youtu.be/kmEDGCNeT0w). Beyond diabetes he is best known for being principle author of the best selling “An Aid to the MRCP Short Cases”, the fourth edition of which is the three volume “An Aid to the MRCP PACES”.